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Abstract
A large proportion of prolactin secreting tumours of
the pituitary gland are treatable by dopamine agonist drugs.
However certain subgroups of these patients are better managed by surgical excision. The indications for surgery in
prolactinomas remain controversial and this paper attempts
to clarify these with illustrative cases. The factors favouring
a surgical approach include poor tolerance of long term
medical therapy, progression of visual deficits or recurrence
while on medical treatment, cystic change in the tumour
with pressure effects, CSF fistula secondary to tumour
shrinkage and prophylactic surgery in tumours anticipated
to cause CSF leak following medical therapy. The size and
invasiveness of the tumour and the prolactin level are also
important determinants of treatment planning. The indications for surgery in prolactinomas are discussed and illustrative cases are presented.

Introduction
The management of prolactinomas has undergone
significant revisions over the course of the last decade.1-4
These changes represent the clinical application of
enhanced understanding of their pathophysiology and
increasingly sophisticated imaging due to technological
developments.2,3 Given the short period over which these
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data have been introduced, it is not surprising that the management of prolactinomas remains controversial.
Prolactinomas can be managed conservatively, medically, surgically or by irradiation.5 The most commonly
modality currently used is medical treatment in the form of
dopamine agonists such as Bromocriptine or newer drugs
such as Cabergoline.1,3 However, several authors assert that
surgery is an effective treatment for prolactinomas.2
Authors in the West have reported cure rates of 70 percent
following transphenoidal surgery for prolactinomas.2
However, to date no work has been done in Pakistan to elucidate the indications for surgery in prolactinomas. We
attempt to clarify the management of this disease by presenting a case series illustrating the indications of surgery
for prolactinomas.

Methods
The medical records of all patients admitted to our
neurosurgical unit with a diagnosis of prolactinoma
between January 1, 1999 to December 31, 2001 were
reviewed retrospectively. Five cases representing the salient
indications of surgery were selected and constituted our
study group. The patient data was transcribed to specially
designed proformas. Patients with prolactin secreting
tumours which were well controlled on medical therapy or
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did not present with surgical indications were excluded
form the study. Data was analyzed by using SPSS version
10 software.

Cases
Patient 1
This 16 year old female patient presented with menorrhagia
and secondary amenorrhoea since the past one year. She
had no neurological deficits. MR scan showed a large sellar
mass with extension into suprasellar cistern (Figure 1). The
prolactin level was 545 ng/dl at initial evaluation. The
patient was started on bromocriptine with a diagnosis of
prolactinoma. However 9 months after the start of treatment
the prolactin level increased to 4443 ng/dl. The tumor was
judged to be unresponsive to bromocriptine and it was
decided to undertake transphenoidal excision of the tumor.
Post-operatively the prolactin level decreased to 30 ng/dl
and the patient remained without neurological deficits. The
estradiol and thyroid hormones were also within normal
limits. The menstrual disturbance resolved after the operation.

Figure 1. T1W MR scan showing a large sellar tumor with central area of low signal signifying
possible cystic change.

Patient 2
This 29 year old female developed amenorrhoea 10 years
prior to presentation. She had no neurological deficits at initial examination and prolactinoma had been diagnosed elsewhere. She had conceived on Bromocriptine treatment 2
years ago. However the patient had recently experienced
increasing nausea which was not being improved by dose
reduction. Recent MR scans showed a large sellar tumor
(Figure 2) and the prolactin level was 831 ng/dl. Since the
patient's nausea was persistent, transphenoidal surgery was
decided. Post-operatively, the prolactin level dropped to 10
ng/dl and the patient was neurologically normal. The nausea
and menstrual disturbances resolved after the operation.
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Figure 2. CT scan with contrast showing a large sellar tumor with central non-enhancing area and
erosion of floor of sella.

Patient 3
This 23 years old female presented with headache and
amenorrhoea of 2 years duration. On examination she was
found to have bi-temporal field defects but no other neurological deficit. MR scan showed a large sellar mass enhancing with contrast but with a central low intensity signal signifying possible cystic changes (Figure 1). The prolactin
level was found to be 3800 ng/dl. The patient was commenced on Bromocriptine with a diagnosis of prolactinoma.
The prolactin level decreased to 1512 ng/dl. However the
visual field deficits progressed considerably during the following 3 months as documented by perimetry. It was decided to undertake transphenoidal excision due to the possibility of persistent compression by the cystic component
which was not responding to bromocriptine. At operation, a
significant cystic component was found and drained along
with excision of the solid part of the tumor. Post-operatively the visual field deficits improved significantly and the
prolactin levels decreased to 28 ng/dl.
Patient 4
This 33 years old male presented with loss of libido since
the past few months. Neurological examination revealed a
bi-temporal hemianopia with no other deficits. Skull radiograph had shown an enlarged pituitary fossa and the serum
prolactin level was 250 ng/dl. The patient was started on
bromocriptine which improved the visual field deficits.
However 4 months later, clear fluid started seeping from the
right nostril. CT scan showed a sellar tumour with erosion
of the sellar floor and herniation of the tumour into the sphenoid sinus (Figure 2). Transphenoidal excision of the tumor
was performed with repair of the sellar floor using fascia
lata, fat and cartilage. The CSF leak stopped post-operatively and the patient remained neurologically intact.
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Patient 5
A 69 year old male presented with decreasing vision in both
eyes since 4 months. Examination revealed bitemporal
hemianopia with no other deficits. MR scan showed a large
sellar tumour with erosion into the sphenoid sinus. The prolactin level was 4105 ng/ dl. It was felt that (there would be
a chance of CSF leakage if the patient was started on
Bromocriptine) due to shrinkage of the invasive tumour. To
obviate this possibility, the sphenoid sinus was surgically
explored, cleared of tumour and the eroded sellar floor was
repaired with a fascial graft secured with fibrin glue. Postoperatively, the patient was commenced on bromocriptine
with prompt improvement of the visual field deficits.

Discussion
The indications for surgery in prolactinomas have
been subject of previous investigations by several
authors.1,2 There have been differing guidelines and recommendations by these studies. It is generally accepted that
dopamine agonists are the first line treatment for most
patients with prolactinomas. However, patient preference is
an important factor in cases where lifelong dopamine treatment is not acceptable and surgical excision is selected.
It is clear that surgery is most useful for small
tumours with prolactin level < 200 ng/dl. However even
larger tumors have certain subgroups which may benefit
from surgery.2 The phenomenon of non-responsiveness to
bromocriptine is well described, although the biochemical
basis remains unexplained.3 The first patient in our group
exhibited this indication and operation yielded good results.
Another indication for surgery in both small and
large tumours is complete intolerance to dopamine agonists
due to gastrointestinal side effects.3 Even though dose
reduction can be tried, but it may not always reduce the
intractable nausea caused by bromocriptine. Our second
case illustrated this problem and transphenoidal surgery
resulted in cure.
Yet another indication for surgery was illustrated by
our third case. This patient had a large tumour with prolactin
levels correspondingly raised to 3800 ng/dl. Although the
prolactin level came down with bromocriptine, the visual
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field deficits progressed. This phenomenon of cystic change
within a prolactinoma has not been well described in the literature. In our view, this constitutes an indication for
transphenoidal surgery.
CSF leakage following commencement of
bromocriptine therapy is a known complication.6 Our fourth
patient developed a CSF fistula during the course of
bromocriptine treatment. This leak was only amenable to
surgical intervention and constitutes another indication for
transphenoidal surgery in prolactinomas. Yet another indication was illustrated by our last case in which the patient
presented with a macroadenoma and the imaging showed a
large sellar mass with erosion of the sellar floor and tumour
extension into the sphenoid sinus. This was treated by
transphenoidal excision and sellar floor repair as it was felt
that bromocriptine treatment would result in CSF leak. This
role of prohylactic surgery to prevent CSF leak has not
been described previously in the literature.
In conclusion, although size of the tumour and prolactin levels appear to be important determinants of decision making, certain over-riding indications for surgery
exist. The authors provide a rationale for trans-sphenoidal
microsurgery in these patients as opposed to other forms of
management, such as bromocriptine therapy and irradiation.
Treatment decisions for prolactinomas need to be individualized for each patient, keeping in view these important
variables.
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